In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Cordaptive: Just Another Cholesterol Combo, or More?

Executive Summary

At first glance, Merck's Cordaptive is yet another combination drug for cholesterol. But by unlocking the significant medical benefits of niacin, the treatment may represent an important advance. Cordaptive contains an anti-flushing agent which reduces the key side-effect preventing wider niacin use.
Advertisement

Related Content

Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity
Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity
Merck Taking Aggressive Approach To Cardiovascular Development
Back to Nature: Prescription Dietary Supplements Cash in on Cholesterol R&D Setbacks
Best of the Blog: IN VIVO, May 2008
Best of the Blog: IN VIVO, May 2008
After Statins, What Next?
The Unsung Vytorin Victim: Primary-Care Marketing
The Unsung Vytorin Victim: Primary-Care Marketing
Rethinking Phase IV: Congress Wants to Get Tough on Post-Marketing Requirements, but FDA May Soften the Blow

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003100

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel